Radiation Oncology Clinical Trials | 黑料官网

Image Guided Radiation Therapy Equipment

黑料官网 Radiation Oncology Clinical Trials

Radiation Oncology offers local multidisciplinary, and radiation therapy-focused clinical trials. The department leads multisite trials through the National Clinical Trials Network Trials (NCTN), and other national and international collaborations. The faculty work on multidisciplinary teams at Froedtert Hospital, Froedtert Hospital community sites, and the Clement J. Zablocki VA Medical Center and advance clinical trials at all sites.

The scientific design behind these studies is developed by the Department of Radiation Oncology and Froedtert & the 黑料官网 partners through an interdisciplinary clinical research approach.
The Froedtert & the 黑料官网 Radiation Oncology team are Principal Investigators (PIs) and Co-Principal Investigators (Co-PIs) on many other multisite trials not listed here.
Even though the trials only list the PIs for each, there are numerous Co-PIs on each trial, and the trials span across all community sites and VA Medical Center, when appropriate.

Investigator-Initiated Trials

all

A Pilot Study Analyzing Pre-Operative Stereotactic Radiosurgery (SRS) with Gamma Knife (GK) for Brain Metastases

Study Short Title: SRS-GK-BRAIN-METAST
Study Design: This is a single-arm, single-center, pilot study in which 10 completed patients with one to four brain metastases diagnosed on brain MRI within the past 30 days will be evaluated for study eligibility and enrolled as appropriate.
Principal Investigator: Joseph Bovi, MD
Phase: Ongoing
Type of Study I: Treatment
Type of Study II: Interventional
Oncology Treatment Group: Central Nervous System

Optimizing NeuroCOgnition with Whole Brain Radiation Therapy (WBRT) using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique (ONCO-RT): A Phase II Trial of Upfront Pulsed Reduced Dose Rate Whole Brain Radiation Therapy for Brain Metastases

Study Short Title: ONCO-RT
Study Design: This will be a phase II, single-arm, multi-center, pilot study assessing the feasibility and impact of substituting PRDR for standard radiation therapy in the upfront treatment of brain metastases on neurocognitive decline as compared to historical controls. This study will enroll 53 patients with radiographically confirmed solid tumor brain metastases.
Principal Investigator: Lindsay Puckett, MD
Phase: II
Type of Study I: Treatment
Type of Study II: Interventional
Oncology Treatment Group: Central Nervous System

Phase II Study Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma (PRORADGLIO Study)

Study Short Title: PRORADGLIO
Study Design: This is a single-arm, single-center phase II study designed to assess the efficacy of pulsed reduced dose-rate radiotherapy in the initial treatment of maximally safely resected glioblastoma. The primary endpoint will be progression-free survival at six months and the study is powered to detect improved PFS of 72% at six months compared with historical control of 50% at six months. Patients with pathologically confirmed GBM who are planned for six weeks of adjuvant chemoradiation followed by six to 12 cycles of adjuvant chemotherapy will be screened and enrolled after surgery. Intention to use TTF/Optune庐 will also be recorded.
Principal Investigator: Michael Straza, MD
Phase: II
Type of Study I: Treatment
Type of Stu